Crisper-based gene editing and anti-aging therapeutics for kidney diseases.

Priti Meena*

Department of Clinical Nephrology, University of São Paulo, Brazil

Introduction

Chronic kidney disease (CKD) and other renal disorders pose significant challenges to global healthcare, affecting millions worldwide. Advances in gene editing, particularly CRISPR-Cas9 technology, offer promising solutions for treating genetic and age-related kidney diseases. Simultaneously, research into renal senescence and anti-aging therapeutics is opening new pathways for prolonging kidney function and delaying age-associated renal decline. This article explores how CRISPR-based gene editing and anti-aging therapies are shaping the future of nephrology [1].

Kidney diseases often have a genetic component, with mutations in specific genes leading to conditions such as polycystic kidney disease (PKD), Alport syndrome, and focal segmental glomerulosclerosis (FSGS). Traditional treatments focus on managing symptoms, but they fail to address the root causes of these disorders. Gene editing technologies like CRISPR offer the ability to precisely modify defective genes, potentially curing hereditary kidney diseases at the genetic level [2].

CRISPR-Cas9 enables targeted DNA modifications, allowing scientists to correct mutations responsible for kidney diseases. Preclinical studies have demonstrated success in repairing genes linked to PKD and other nephropathies in animal models. Researchers are now exploring safe and efficient delivery methods, such as viral and non-viral vectors, to apply CRISPR-based therapies in human kidneys [3].

Despite its potential, CRISPR-based therapies face significant challenges, including off-target effects, immune responses, and ethical considerations. Ensuring precise gene editing without unintended genetic alterations is critical to the safe application of this technology. Additionally, regulatory approvals and long-term studies are needed to validate its efficacy and safety in humans [4].

Aging is a major risk factor for CKD, as kidney function naturally declines with age. Cellular senescence, characterized by the accumulation of damaged and dysfunctional cells, plays a crucial role in renal aging. Senescent cells secrete inflammatory molecules that contribute to fibrosis and kidney dysfunction, accelerating age-related renal diseases [5].

Emerging anti-aging therapies aim to combat renal senescence and extend kidney health. Senolytics, a class of drugs that selectively eliminate senescent cells, have shown promise in reducing inflammation and fibrosis in aged kidneys. Other interventions, such as NAD+ boosters and caloric restriction mimetics, help improve mitochondrial function and cellular repair mechanisms [6].

Combining CRISPR-based gene editing with anti-aging strategies could revolutionize nephrology. By correcting genetic defects and simultaneously targeting aging pathways, researchers could develop comprehensive treatments that not only cure inherited kidney diseases but also slow age-related renal decline. This dual approach may significantly enhance kidney health and longevity [7].

Several clinical trials are underway to evaluate the effectiveness of gene editing and anti-aging interventions for kidney diseases. Researchers are testing CRISPR-based therapies in rare genetic nephropathies, while pharmaceutical companies are exploring senolytics for age-related renal conditions. The success of these trials will determine the feasibility of widespread clinical applications [8].

As with any emerging technology, ethical concerns must be addressed before CRISPR and anti-aging therapeutics become mainstream treatments. Ensuring equitable access, preventing misuse, and establishing rigorous safety protocols are crucial steps in integrating these innovations into clinical practice [9, 10].

Conclusion

CRISPR-based gene editing and anti-aging therapeutics hold immense promise for revolutionizing the treatment of kidney diseases. While challenges remain, ongoing research and clinical trials are paving the way for safer and more effective interventions. By combining genetic corrections with anti-aging strategies, the future of nephrology could witness groundbreaking advancements that improve kidney health and enhance longevity for millions of patients worldwide.

References

1. Ding M, Lu X, Wang C, et al. The E2F1-miR-520/372/373-SPOP axis modulates progression of renal carcinoma. Cancer Res. 2018;78(24):6771-84.
2. Ganguly S, Chandra A, Chatterjee IB. Pathobiology of cigarette smoke-induced invasive cancer of the renal pelvis and its prevention by vitamin C. Toxicol Rep. 2018;5:1002-10.

***Correspondence to:** Priti Meena, Department of Clinical Nephrology, University of São Paulo, Brazil. E-mail: priti@meena.br

***Received:** 2-Feb-2025, Manuscript No. AACNT-25-161912; **Editor assigned:** 3-Feb-2025, PreQC No. AACNT-25-161912(PQ); **Reviewed:** 16-Feb-2025, QC No. AACNT-25-161912; **Revised:** 20-Feb-2025, Manuscript No. AACNT-25-161912(R); **Published:** 27-Feb-2025, DOI: 10.35841/aacnt-9.1.249*

***Citation:** Meena P. Crisper-based gene editing and anti-aging therapeutics for kidney diseases. J Clini Nephrol. 2025; 9(1):249.*

3. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74-84.

4. Dabestani S, Marconi L, Kuusk T, et al. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol. 2018;36(12):1953-9.

5. Joshi SS, Handorf EA, Zibelman M, et al. Treatment facility volume and survival in patients with metastatic renal cell carcinoma: a registry-based analysis. Eur Urol. 2018;74(3):387-93.

6. de Lusignan S, Chan T, Stevens P, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22(3):234-41.

7. Parikh NI, Hwang SJ, Larson MG, et al. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol. 2008;102(1):47-53.

8. de Mutsert R, Snijder MB, van der Sman-de Beer F, et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol. 2007;18(3):967-74.

9. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48.

10. Goldwasser P, Mittman N, Antignani A, et al. Predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 1993;3(9):1613-22.

Citation: *Meena P. Crisper-based gene editing and anti-aging therapeutics for kidney diseases. J Clini Nephrol. 2025; 9(1):249.*